Pharma Update

Roche Roche: A leader in malignant and non-malignant hematology Launching new standards of care • Hemlibra in hemophilia A Polivy + R-CHP in 1L DLBCL • Lunsumio in 3L+ FL • Columvi in 3L+ DLBCL Investing in growing & new indications • Established leader in DLBCL, FL, CLL and hemophilia A Expansion potential in malignant (AML, MM, MDS, MCL) and in non- malignant hematology (PNH, aHUS, SCD) 00 Broad portfolio enables novel combinations • • 7 medicines on the market and 10 NMEs in clinical development Novel combinations in NHL (e.g. Polivy + CD20xCD3 bispecifics; Columvi + costimulatory molecules) • Exploring different modalities Bispecific antibodies Antibody drug conjugates Improving patient/ provider experience Fixed duration Simple dosing schedule • Recycling antibody technology . Off-the-shelf availability • Gene therapy • Allogeneic CAR-T Outpatient administration DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; CLL=chronic lymphocytic leukemia; MM-multiple myeloma; AML-acute myeloid leukemia; MDS=myelodysplastic syndromes; MCL-mantle cell lymphoma; CAR- T=chimeric antigen receptor T-cell; R-CHP-rituxan + cyclophosphamide + doxorubicin + prednisone; PNH-Paroxysmal Nocturnal Hemoglobinuria; aHUS-atypical Hemolytic Uremic Syndrome; SCD-Sickle Cell Disease; NHL-Non- Hodgkins lymphoma; NME-New Molecular Entity 83 83

View entire presentation